An open-label naturalistic pilot study of acamprosate in youth with autistic disorder. - Wikidata - awgldk - TriplyDB

An open-label naturalistic pilot study of acamprosate in youth with autistic disorder.

An open-label naturalistic pilot study of acamprosate in youth with autistic disorder.

http://www.wikidata.org/entity/Q35625886

about

Identification and Treatment of Pathophysiological Comorbidities of Autism Spectrum Disorder to Achieve Optimal Outcomes.The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment.Translational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics.Pharmacological means of reducing human drug dependence: a selective and narrative review of the clinical literature.Impact of acamprosate on plasma amyloid-β precursor protein in youth: a pilot analysis in fragile X syndrome-associated and idiopathic autism spectrum disorder suggests a pharmacodynamic protein marker.The role of metabotropic glutamate receptor 5 in the pathogenesis of mood disorders and addiction: combining preclinical evidence with human Positron Emission Tomography (PET) studies.GABA system dysfunction in autism and related disorders: from synapse to symptoms Increased glutamate concentration in the auditory cortex of persons with autism and first-degree relatives: a (1)H-MRS study Pharmacotherapy for the core symptoms in autistic disorder: current status of the research Multiple Drug Treatments That Increase cAMP Signaling Restore Long-Term Memory and Aberrant Signaling in Fragile X Syndrome Models.The role of ionotropic glutamate receptors in childhood neurodevelopmental disorders: autism spectrum disorders and fragile x syndrome.Impaired activity-dependent neural circuit assembly and refinement in autism spectrum disorder genetic models.Social Communication is an Emerging Target for Pharmacotherapy in Autism Spectrum Disorder - A Review of the Literature on Potential Agents.An update on medication management of behavioral disorders in autism.What's in the pipeline? Drugs in development for autism spectrum disorder.Pharmacological Modulation of GABA Function in Autism Spectrum Disorders: A Systematic Review of Human Studies.Is Taurine a Biomarker in Autistic Spectrum Disorder?Lurasidone for the treatment of irritability and anger in autism spectrum disorders.Pediatric Traumatic Brain Injury and Autism: Elucidating Shared Mechanisms.Brief report: Pilot single-blind placebo lead-in study of acamprosate in youth with autistic disorder.Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome.

P2860

Q26744037-BE2F4007-F068-4FED-B678-E2F35307BF2C Q26998975-8D687FD6-BCDE-4361-B63D-4CDC90B63467 Q28394524-EAF3337C-9B3D-4FD3-AE77-B32A58D5B948 Q33582063-B1CB7EDA-6554-40D7-B782-985CFEAC5069 Q34620558-3203A589-16B9-45E0-8CEA-4C5F151DEDD4 Q35190052-67A10A26-F827-4953-90C6-B4C645D5EA62 Q35770888-4DFFA2D7-3E5E-48D7-9B56-B2CAAFFDA1A3 Q36632136-713BEAAD-D9CE-4D35-84E1-AAF5E9F3F511 Q36784208-45C069C5-76C7-4680-A3D5-658F3EFAFD2B Q37054398-DD70E1DF-DF51-4D7D-9326-F14DC7F8A8E0 Q37559828-1F71B4C1-4C19-4129-A3F6-FD58E6758468 Q37564195-72BC60E4-286B-4594-BD3C-C90D5A043C5F Q37567431-4D8F120A-EC11-4446-B053-28149BD48161 Q38184482-7C9AFD73-31E5-4341-92A1-E598B32839AB Q38193069-3887CBBB-24AA-450B-8E6C-3C397952B763 Q38601092-A9616094-1B44-4309-89D8-11EA05344A8C Q38604354-4BD1CFA3-2C20-4DD1-9494-65B9E97CC112 Q38689883-7148E2F0-8E90-4436-A0D5-D3C32BD46D04 Q39028166-91C8AB6D-42CD-4BC3-A3B1-5BB27BA5E0B1 Q39347371-EC001431-813C-4B62-A6F9-AD9F3F0B4DEF Q39462489-2D5B6D02-D012-4CB3-BFE9-0BE9B48B3AD2

P2860

An open-label naturalistic pilot study of acamprosate in youth with autistic disorder.

http://www.wikidata.org/entity/Q35625886

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

An open-label naturalistic pilot study of acamprosate in youth with autistic disorder.

@ast

An open-label naturalistic pilot study of acamprosate in youth with autistic disorder.

@en

type

label

An open-label naturalistic pilot study of acamprosate in youth with autistic disorder.

@ast

An open-label naturalistic pilot study of acamprosate in youth with autistic disorder.

@en

prefLabel

An open-label naturalistic pilot study of acamprosate in youth with autistic disorder.

@ast

An open-label naturalistic pilot study of acamprosate in youth with autistic disorder.

@en

P1433

Q35625886-565E42F8-B28E-4E1F-9C3E-2B1BD1BB79EC

P1476

Q35625886-F261431C-9AA8-4D46-8A30-BE0BEA770B87

P2093

Q35625886-0388070F-A3F4-4205-8D80-87B76ABA8085

Q35625886-094838E6-A0D3-4315-AECC-73EE486AB7A0

Q35625886-1FD095AE-4C4B-4BCA-A80F-67C902147FCC

Q35625886-29D4A7E4-2EF0-418B-BC3F-0B462E2D8D16

Q35625886-725D7BE2-112B-4295-AADC-E032C5BF8322

P2860

Q35625886-02DE1C37-E157-4D33-85D7-5DF433485176

Q35625886-0C9878A2-BE29-41B3-AFDC-19D07577A1A7

Q35625886-231D8092-C9A8-4590-BB71-90CB75246C51

Q35625886-2A9F8CBA-3792-423B-BCD1-1D898A175707

Q35625886-3179E940-79C5-49F9-B832-39F2582CC906

Q35625886-36ECE530-32F3-448E-A24F-ABCC593EB393

Q35625886-36FD5E25-39D6-4BC8-BDC0-0847A519121C

Q35625886-38996428-31CD-4A0B-9259-949F31FB77D5

Q35625886-4A1167F4-88D9-4688-93BF-DBA171940A52

Q35625886-4E61FEF0-F465-4575-80C1-221C7E16CD83

P304

Q35625886-43BED7F0-DEBE-436A-8B5B-8FBB03D59DA4

P31

Q35625886-A2D61B35-82C4-4CA3-9DE5-E9ECF875F265

P356

Q35625886-BA32C58B-8F90-4A79-9E9F-EB1846DA475A

P433

Q35625886-28F8DD97-3A31-46FC-9667-9EE7151B013B

P478

Q35625886-6807C2F9-AFE9-4CB1-B82A-A56BBD01E4E6

P50

Q35625886-26FD7D1C-C779-4744-BD2E-A15FBD30007D

P577

Q35625886-99A69C1F-DA73-468E-9EFF-B1D230B26165

P5875

Q35625886-78301F24-B268-4078-8C6D-1AF94478C621

P698

Q35625886-66D0A7AB-9827-41E2-B485-7B6387ABA155

P921

Q35625886-1252CB02-772A-4C0A-9794-23AFC6F9C072

P932

Q35625886-0B0A3CE6-96C5-42DA-AA1F-5F17B69DF0B4

P356

P1433

Journal of Child and Adolescent Psychopharmacology

P1476

An open-label naturalistic pilot study of acamprosate in youth with autistic disorder.

@en

P2093

Craig A Erickson

http://www.w3.org/2001/XMLSchema#string

Jennifer E Mullett

http://www.w3.org/2001/XMLSchema#string

Kimberly A Stigler

http://www.w3.org/2001/XMLSchema#string

Logan K Wink

http://www.w3.org/2001/XMLSchema#string

Maureen Early

http://www.w3.org/2001/XMLSchema#string

P2860

Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence

15q11-13 GABAA receptor genes are normally biallelically expressed in brain yet are subject to epigenetic dysregulation in autism-spectrum disorders

A retrospective study of memantine in children and adolescents with pervasive developmental disorders

Acamprosate: recent findings and future research directions

The mGluR theory of fragile X mental retardation

The pharmacotherapy of target symptoms associated with autistic disorder and other pervasive developmental disorders.

Naltrexone in autistic children: behavioral symptoms and attentional learning.

Increased serum levels of glutamate in adult patients with autism.

Secretin is an ineffective treatment for pervasive developmental disabilities: a review of 15 double-blind randomized controlled trials.

Developing drugs for core social and communication impairment in autism.

P304

565-569

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1089/CAP.2011.0034

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Christopher J McDougle

P577

2011-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51848335

http://www.w3.org/2001/XMLSchema#string

P698

22136091

http://www.w3.org/2001/XMLSchema#string

P921

P932

3243460

http://www.w3.org/2001/XMLSchema#string